Fargren 2014.
Methods | A single‐centre, double‐blind, randomised, placebo‐controlled cross‐over study |
Participants | Participants with type 2 diabetes, mean age 59 + 6 (SD) years and mean HbA1c 7.7% + 0.8%, treated with exogenous insulin with or without oral antihyperglycaemic agents |
Interventions | Participants received vildagliptin (50 mg twice a day) or placebo as add‐on to insulin for 4 weeks in random order with a 4‐week washout in between |
Outcomes | Glucose, glucagon |
Notes | ‐ |